Journal
BLOOD
Volume 115, Issue 10, Pages 2008-2013Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-04-217224
Keywords
-
Categories
Funding
- Inserm
- ANR [ANR-07-JCJC-0093-01]
- Fondation pour la Recherche Me dicale, France [FRM-SPE20051105175]
- EMBO [ALTF676-2005]
- European Union [MEIF-CT-2006-039676]
- Agence Nationale de la Recherche (ANR) [ANR-07-JCJC-0093] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
During platelet activation, phosphoinositide 3-kinases (PI3Ks) produce lipid second messengers participating in the regulation of functional responses. Here, we generated a megakaryocyte-restricted p110 beta null mouse model and demonstrated a critical role of PI3K beta in platelet activation via an immunoreceptor tyrosine-based activation motif, the glycoprotein VI-Fc receptor gamma-chain complex, and its contribution in response to G-protein-coupled receptors. Interestingly, the production of phosphatidylinositol 3,4,5-trisphosphate and the activation of protein kinase B/Akt were strongly inhibited in p110 gamma null platelets stimulated either via immunoreceptor tyrosine-based activation motif or G-protein-coupled receptors. Functional studies showed an important delay in fibrin clot retraction and an almost complete inability of these platelets to adhere onto fibrinogen under flow condition, suggesting that PI3K beta is also acting downstream of IIb beta 3. In vivo studies showed that these mice have a normal bleeding time and are not protected from acute pulmonary thromboembolism but are resistant to thrombosis after FeCl3 injury of the carotid, suggesting that PI3K beta is a potential target for antithrombotic drugs. (Blood. 2010; 115: 2008-2013)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available